COSTA MESA, Calif., June 26, 2015 /PRNewswire-iReach/ -- WCCT Global, a full service contract research organization headquartered in Southern California, announced today a sizable investment from Asian private equity firm Medivate Partners (www.mvphia.com). With access to these funds, WCCT Global is pursuing both strategic organic expansion and new research capabilities within Asia and Europe, with the intent of improving their early and late phase contract research services in the areas of influenza, respiratory, ophthalmology, nephrology, rare diseases, and oncology, expanding their unique patient recruitment models, and acquiring new sites that give access to special populations.
Photo - http://photos.prnewswire.com/prnh/20150625/225880
WCCT Global’s CEO Dr. Kenneth Kim stated, “We are pleased to move into this exciting chapter as WCCT Global continues to grow through strategic partnerships and acquisitions. We are committed to providing industry leading services that exceed the industry’s expectations of what can be provided by a contract research organization.”
Medivate Partners was founded by former Novartis Ventures & POSCO BioVentures Managing Director Paul Kim, and typically invests $10M ~ $30M growth capital equity in life science companies in Asia and North America.
“We are excited by WCCT’s strategic organic growth strategies and expansion opportunities in Asia and abroad”, said Mr. Kim. “Strong demand for global pharmaceutical outsourcing continues, and the contract research organization is well positioned to capture this growth as well as exploding growth in Asia,” he added.
More about WCCT Global
WCCT Global is a multi-site, full service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.
More about Medivate Partners
Medivate Partners is a healthcare-focused investment firm targeting Asia-Pacific and US markets. Asia-Pacific healthcare expenditure is expected to grow 75% from 2011 to 2015, representing a third of global healthcare market revenue. MediVate is well positioned to capture surging healthcare investment opportunities between Asia and US / EU, and looks to arbitrage the unique cross border investment advantages.
Media Contact:Matt Miller, WCCT Global, 714.668.1500 ext.2029, Matt.Miller@wcct.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE WCCT Global
Help employers find you! Check out all the jobs and post your resume.
